



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/598,275	03/28/2007	Ryozo Nagai	P30563	2170	
7055	7590	02/02/2011 GREENBLUM & BERNSTEIN, P.L.C. 1950 ROLAND CLARKE PLACE RESTON, VA 20191			
		EXAMINER PURDY, KYLE A			
		ART UNIT 1611		PAPER NUMBER 1611	
NOTIFICATION DATE	DELIVERY MODE				
02/02/2011	ELECTRONIC				

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

gbpatent@gbpatent.com  
pto@gbpatent.com

Applicants arguments filed 1/18/2011 regarding the rejection of claims 24, 28, 29 and 32-40 made by the Examiner under 35 USC 103(a) over Marx in view of Shidoji, evidenced by English equivalent US 2005/0250671 have been fully considered but they are not found persuasive and are **MAINTAINED**.

In regards to the 103(a) rejection, Applicant asserts the following:

A) the claims now recite (2E,4E,6E,10E)-3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid.

In response to A, Applicants argument is not persuasive because this very same compound is taught by Shidoji and its use in a method for the treatment of arteriosclerosis would have been obvious. A